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Abstract
Background: In patients treated with bevacizumab, hypertension may be a biomarker 
of therapeutic efficacy. However, it is not clear whether drugs that control blood pres-
sure influence bevacizumab's efficacy. In this study, we investigated drugs that may 
affect hypertension in bevacizumab-treated patients and examined the impact on the 
therapeutic effect.
Patients and methods: We analyzed 3,724,555 reports from the third quarter of 
2010 to the second quarter of 2015. All data were obtained from the Food and Drug 
Administration (FDA) Adverse Event Reporting System (FAERS) analysis. In this 
retrospective cohort study, we investigated a total of 58 patients diagnosed with colo-
rectal cancer and treated for the first time with bevacizumab containing XELOX or 
mFOLFOX6 at The University of Tokushima Hospital between January 2010 and 
December 2015. The effect of the treatment was evaluated according to Response 
Evaluation Criteria in Solid Tumors version 1.0. Thereafter, the effect was confirmed 
using Gene Expression Omnibus (GEO) and cultured cells.
Results: There are few reports in FAERS of hypertension in patients treated with 
omeprazole on bevacizumab. Based on the chart review, patients who used proton 
pump inhibitors (PPI) had a lower response to treatment than those who did not (re-
sponse rate: 25% vs 50%). Furthermore, experiments on GEO and cell lines suggested 
that induction of vascular endothelial growth factor (VEGF) gene expression by PPIs 
is the cause of the reduced therapeutic effect.
Conclusion: PPIs prevent hypertension in bevacizumab-treated patients but may re-
duce bevacizumab's anti-tumoral effects by inducing VEGF expression.
K E Y W O R D S
bevacizumab, colorectal cancer, FAERS, gene expression omnibus, hypertension, proton pump inhibitor
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1 |  INTRODUCTION
Bevacizumab is a humanized monoclonal antibody against 
the vascular endothelial growth factor (VEGF) that inhibits 
tumor growth by inhibiting angiogenesis. It has shown an-
titumor effects in several cancer types, including colorectal 
cancer, breast cancer, non-small cell lung cancer, renal cell 
carcinoma, ovarian cancer, glioblastoma, and metastatic mel-
anoma.1–3 Bevacizumab has been used in combination with 
chemotherapy, and has been reported to prolong both overall 
survival and progression-free survival.4–6 However, bevaci-
zumab causes a variety of adverse events, one of which is 
hypertension. One clinical study reported that after bevaci-
zumab treatment, 49.3% of patients had induced-grade 2, or 
higher hypertension.3
Hypertension induced by bevacizumab administration is 
thought to occur due to decreased endothelial cell regenera-
tive capacity and decreased production of vasodilators, such 
as nitric oxide and prostacyclin.7 VEGF inhibition leads to 
the reduction of nitric oxide synthesis, thus reducing the lev-
els of nitric oxide in the body,7 which in turn leads to con-
striction of the blood vessels, and a reduction in sodium ion 
renal excretion, ultimately resulting in hypertension.8 The 
development of bevacizumab-induced hypertension is one of 
the most important problems in continuing the bevacizumab 
treatment, and even deaths have been reported due to the 
development of hypertension. If bevacizumab-induced hy-
pertension develops, bevacizumab should be stopped imme-
diately until blood pressure control is achieved.9–11
However, several retrospective studies have suggested that 
among patients treated with bevacizumab, those who devel-
oped hypertension had a better prognosis than those who did 
not.8,12–15 Indeed, in patients with metastatic colorectal cancer 
who received combination chemotherapy with bevacizumab, 
overall response, progression-free survival, and overall sur-
vival were associated with the emergence of hypertension.13 
These studies suggest that the appearance of hypertension 
may be a biomarker of treatment efficacy in patients treated 
with bevacizumab. In addition, it is possible that drugs re-
ducing the occurrence of hypertension in patients receiving 
bevacizumab might have a negative effect on the efficacy of 
bevacizumab treatment, however, their associations are cur-
rently not clear. Most patients treated with bevacizumab use 
several concomitant drugs. Among these concomitant drugs, 
there might be several drugs that could alter the blood pres-
sure, but to the best of our knowledge, there are no studies on 
the interactions of these drug combinations. This could be 
probably explained partly by the fact that concomitant med-
ications are so varied that it would be difficult to adequately 
study them in studies involving a small number of centers.
The Food and Drug Administration (FDA) Adverse 
Event Reporting System (FAERS) is the world's largest da-
tabase created by the U.S. FDA to monitor the safety risks 
of approved drugs. Adverse events related to drug use are 
voluntarily reported to FAERS by patients, physicians, phar-
macists, and other health care providers. Currently, millions 
of drug-related adverse events are registered in FAERS, 
which in recent years has supported several academic stud-
ies on drug safety and development that are separate from 
the FDA’s objective of monitoring drug adverse events. 
For example, FAERS analysis has shown that concomitant 
drug B reduces the risk of adverse events caused by drug 
A.16,17 Additionally, the Gene Expression Omnibus (GEO) 
is a global data repository of next-generation sequencing, 
microarray, and high-throughput functional genomics data 
submitted by research communities.18 It is also an integrated 
database for systematic analyses of gene function and linking 
gene information with higher-order functional information.19 
We have previously analyzed large information databases, 
such as FAERS and GEO to identify novel drug effects of 
existing drugs.20–22
These databases have enabled us to analyze the effects 
of concomitant drugs, and to estimate the mechanisms of 
their effects, which otherwise cannot be analyzed in a few 
centers due to the inadequate number of cases. Therefore, in 
this study, we aimed to investigate drugs that could alter the 
incidence of hypertension in bevacizumab-treated patients 
and examine whether these drugs could affect the treatment 
efficacy.
2 |  RESULTS
2.1 | FAERS analysis for determining 
the relationship between bevacizumab and 
hypertension
The FAERS database was used to investigate the occurrence 
of hypertension in patients treated with bevacizumab. Of 
36,95,466 patients, hypertension was reported in 85,079 pa-
tients and in 1,520 using bevacizumab. The reporting odds 
ratio (ROR) for bevacizumab use and hypertension was 2.45, 
95% confidence interval (CI): 2.33–2.59, p < 0.001, which in-
dicated a strong relationship. A similar relationship was found 
when the patients were stratified by sex and age (Table 1). 
Bevacizumab was found to be associated with an increased 
incidence of hypertension in FAERS, regardless of age or sex.
2.2 | FAERS-based search for drugs 
reducing hypertension in patients treated with 
bevacizumab
The FAERS was used to identify concomitant drugs that 
were associated with a reduced incidence of hypertension in 
patients treated with bevacizumab. Epirubicin, Erlotinib, and 
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omeprazole were found to be associated with a lower rate of 
hypertension in patients treated with bevacizumab (Table 2) 
in the FAERS analysis. However, among them, patients using 
omeprazole reported the highest incidence of hypertension.
2.3 | Demographic and clinical 
characteristics of patients by examining their 
medical records
Between January 2010 and December 2015, 62 patients 
from The Tokushima University Hospital were treated with 
bevacizumab in combination with XEROX or mFOLFOX6, 
among whom 58 were included in the analysis. Table 3 shows 
the patients’ characteristics in the PPI (n = 16) and non-PPI 
(n = 42) groups. There were no significant differences be-
tween the two groups regarding median age at diagnosis, sex, 
performance status (PS), histopathological staging, concomi-
tant regimens, or concomitant antihypertensive medications 
(Table 3).
2.4 | Influence of PPI-use on the 
effectiveness of chemotherapy, including 
bevacizumab
Response rates were measured. No patient had complete 
response (CR), 25 had partial response (PR), 24 had stable 
disease (SD), and 9 had progressive disease (PD). The re-
sponse rate was 50% in the non-PPI group and 25% in the PPI 
group; objective response rate (ORR) was 25% higher in the 
non-PPI group than that in the PPI group, with no significant 
difference. The disease control rate was 50% in the non-PPI 
group and 25% in the PPI group. The disease control rate of 
the non-PPI group was 21% higher than the PPI group but not 
significant (Table 3).
In both groups, the blood pressure increased after bevaci-
zumab treatment. The change in mean systolic blood pressure 
before and after bevacizumab treatment was 13.55 mmHg in 
the non-PPI group and 13.94 mmHg in the PPI group, with 
no significant difference (Table 4).
2.5 | Evaluating changes in signaling 
pathways and gene expression associated 
with the pathway of hypertension using the 
GEO and Kyoto Encyclopedia of Genes and 
Genomes (KEGG) databases
To investigate the mechanism of effect of bevacizumab in 
patients using omeprazole, we analyzed a GEO-deposited 
toxicogenomics microarray dataset (GEO Association No. 
GSE59927). Using these data sets, we analyzed the differ-
ences in gene expression in rats treated orally with omepra-
zole (30 mg/kg, for 5 days) (Table 5). GEO analysis showed 
that VEGF gene expression was upregulated in the rat livers 
after oral omeprazole treatment.
2.6 | Effect of PPI on VEGFA expression 
using human cell lines
The influence of PPI on VEGF gene expression was evalu-
ated using human vascular endothelial cells (HUVEC). 
Exposure of PPIs (omeprazole, rabeprazole, lansoprazole, 
pantoprazole, and esomeprazole; 100  μM) increased cell 
proliferation significantly in HUVEC, as did the exposure 
of VEGF. However, there were no significant increases with 
exposure of famotidine. Thus, the effect of PPI on VEGF-A 
mRNA expression was then evaluated using LS174T cells. 
VEGF-A mRNA expression was significantly increased 
by PPI exposure in LS174T cells. However, there was no 





bevacizumab (%) ROR 95%CI p-value
Total 83559/3695466 (2.26) 1520/28288 (5.37) 2.45 2.33-2.59 <0.001
Stratified by gender
Male 28076/1274753 (2.2) 414/11466 (3.61) 1.66 1.51-1.84 <0.001
Female 51603/2090097 (2.47) 776/13658 (5.68) 2.38 2.21-2.56 < 0.001
Stratified by age (y)
<40  8342/527869 (1.58) 60/1232 (4.87) 3.19 2.46-4.14 <0.001
40~4 7758/321558 (2.41) 104/1998 (5.21) 2.22 1.82-2.71 <0.001
50~59 13054/470547 (2.77) 214/4062 (5.27) 1.95 1.7-2.24 <0.001
60~69 14250/472096 (3.02) 299/5476 (5.46) 1.86 1.65-2.09 <0.001
70~100 15478/529240 (2.92) 248/4663 (5.32) 1.86 1.64-2.12 <0.001
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significant increase in exposure of famotidine (Figure 1). 
Cobalt Chloride (CoCl2) was used as positive control.
3 |  DISCUSSION
In this study, we identified drugs that reduced the occur-
rence of hypertension in patients treated with bevacizumab 
and then investigated whether these drugs could reduce 
the efficacy of bevacizumab. We used FAERS to identify 
that among patients treated with bevacizumab, there were 
fewer reports of hypertension in patients taking omepra-
zole. However, the other PPIs did not show an association 
with the reduction in the occurrence of hypertension in pa-
tients treated with bevacizumab. This may be due to the 
long period of time since omeprazole was approved and 
the high number of reports compared with the number of 
adverse event reports for other PPIs in the FAERS data-
base. For large databases such as FAERS, it is difficult 
to achieve unsupervised collection results and some data 
may be inaccurate.20,21 Furthermore, there are no data on 
individual patient characteristics. Therefore, we retrospec-
tively investigated the medical records of patients in our 
hospital.
In the clinical records study, we examined the association 
between the use of PPIs and response rates. There was a 25% 
(though not statistically significant) reduction in the ORR 
and 21% reduction in the disease control rate in patients using 
PPIs. Thus, there was a reduction in the response to bevaci-
zumab combination chemotherapy. There were no significant 
differences between the two groups for factors such as stage, 
PS, or combination regimen.
Although FAERS analysis showed a reduced rate of bev-
acizumab-induced hypertension in patients using PPIs, but 
there was no significant reduction in the chart reviews. This 
may be because many patients in our hospital had developed 
hypertension before bevacizumab was administered and were 
already satisfactorily treated with antihypertensive drugs. 
Furthermore, the PPI group might have had lower numbers 
of hypertensive patients, which may have prevented them 
from achieving significant results. This study suggests that 
PPI not only reduces the incidence of hypertension in patients 
treated with bevacizumab but also reduces the efficacy of this 
drug. However, this study did not examine the duration of PPI 
T A B L E  2  Concomitait drugs that decrease occurrence of bevacizumab-induced hypertension in FDA Adverse Event Reporting System
Drug B
Hypertension without drug 
B (%)
Hypertension with drug 
B (%) ROR 95% CI p-value
EPIRUBICIN 1512/27859 (5.43) 8/429 (1.86) 0.33 0.16-0.67 <0.001
ERLOTINIB 1486/27390 (5.43) 34/898 (3.79) 0.69 0.49-0.97 0.035
OMEPRAZOLE 1502/27692 (5.42) 18/596 (3.02) 0.54 0.34-0.87 0.008
T A B L E  3  Baseline patient characteristics and Responses 





Median age, y 
(range)
68 (40-86) 62 (42-82) 0.188a 
Gender, n (%)
Male 21 (50) 10 (63) 0.5765b 
Female 21 (50) 6 (38)
Stage
Ⅰ 1 (2) 0 0.8241c 
Ⅱ 1 (2) 0
Ⅲa 5 (12) 1 (6)




0 21 (50) 8 (50) 0.7633b 
1 23 (48) 7 (44)
2 0 (2) 1 (6)
Combined 
regimes
XELOX 21 (42) 12 (75) 0.1551b 
mFOLFOX6 21 (42) 4 (25)
Anti 
hypertensive
Use 7 (17) 3 (19) 1c 








50% 25% 0.138c 
Disease control 
rate
90% 69% 0.097c 
Abbreviations: CR, complete response; PD, progression dessease; PR, partial 
response; SD, stable disease.
aMann-Whitney U test. 
bChi-square test. 
cFisher's exact test. 
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dosing, and further investigation is needed to determine the 
extent to which PPI-use influences the effects and adverse 
events of bevacizumab.
We investigated the molecular mechanisms by which the 
combination of PPI and bevacizumab was found to be asso-
ciated with poor antitumor effect. We analyzed the GEO da-
tabases and found that PPI induces VEGF gene expression. 
It has also been previously suggested that drugs that inhibit 
VEGF expression reduce VEGF-induced angiogenesis.23 
This suggests that PPI might reduce the therapeutic effect of 
bevacizumab by inducing the expression of VEGF.
Therefore, we then investigated the effects of PPIs on 
tumor growth and angiogenesis using the human cell lines. 
We found that PPIs promoted cell proliferation in the vas-
cular endothelial cell line HUVEC. The inhibition of an-
giogenesis was related to the mechanism of tumor growth 
inhibition by bevacizumab,24,25 suggesting that the promo-
tion of angiogenesis by PPIs in tumor tissues might have led 
to a lower response rate in patients using PPI. Next, using 
the colon cancer cell line LS174T, we revealed that PPIs 
promoted the expression of the VEGF mRNA expression 
in the tumor cells. These results indicated that PPI induced 
VEGF expression in tumor cells might have promoted the 
angiogenesis and cancer cell growth. This could be the 
mechanism that led to the reduced therapeutic efficacy of 
bevacizumab in the medical records study. This effect may 
also vary according to cancer type and should be further 
investigated for other types of cancer. However, it has been 
reported that PPIs have an enhanced antitumor effect in pan-
creatic cancer.26 Therefore, for anti-tumor agents other than 
bevacizumab, PPIs may have a synergistic effect by mecha-
nisms other than VEGF.
There are possible limitations in this study. FAERS analysis 
includes reporting bias and unmeasured confounding factors. 
Furthermore, not all adverse events observed in clinical prac-
tice are included in the database. Under reporting or selective 
reporting might be included. Because the FAERS database 
contains missing data, incorrect drug names, and duplicate 
data, we removed or corrected such data before the analysis. 
The FAERS analysis showed that some variables were also 
limited. We also did not consider race, duration of treatment, 
drug dosage, or co-administration of other medications. 
Although hypertension may have occurred prior to treatment 
as an underlying condition, the treatment time and the other 
medications were not listed in the FAERS database. While 
these aforementioned factors might affect the results, the use 
of self-reporting systems can be useful in detecting potential 
drug signals. Moreover this was a single-center study and was 
limited to a specific type of cancer, thus, a multicenter study 
with a larger cohort is required. Additionally, the relationship 
between the PPI and the treatment effect of bevacizumab has 
not been examined because not enough cases have been col-
lected for evaluation. Therefore, further studies are needed to 
conclude the possibility of PPIs decreasing the therapeutic ef-
fect of bevacizumab. Furthermore, further studies, including 
multicenter and randomized trials, may be considered.
However, we should never dismiss the use of PPIs. PPIs 
are very important in many diseases such as gastric ulcers 
and reflux esophagitis. However, the long-term use of PPIs 
may be a risk factor for stomach cancer,27,28 and shorter prog-
nosis for lung cancer patients receiving immune checkpoint 
inhibitors.29,30 Thus, although PPIs are currently effective in 
gastric conditions and are frequently used, they may not be 
used properly.31,32 It may be necessary to avoid long-term 
administration of PPI which should be administered to only 
those who truly require it.
mean systolic blood pressure (SD)
before treatment with 
bevasizumab [mmHg]
after treatment with 
bevasizumab [mmHg] p- value
Non-PPI group 130 (15.33) 143 (19.55) 0.979a 
PPI group 120 (5.39) 134 (4.56)
aMann-Whitney U test. 
T A B L E  4  Systolic blood pressure 
before and after bevacizumab treatment in 
non-proton pump inhibitors (PPI) and PPI 
groups.
T A B L E  5  Gene Expression Omnibus data showing the effects of 
omeprazole on the expression levels of vascular endothelial growth 
factor signaling-related genes.
Gene title Omeprazole Corn Oil p-value
vascular endothelial growth 
factor
11.57 11.07 0.048
SPHK1 (sphingosine kinase 
type 1) interacting protein 
(Hs.) (DBSS)
5.05 5.69 0.003
neuroblastoma RAS viral  
(v-ras) oncogene homolog
7.31 7.53 0.006
v-raf-1 murine leukemia viral 
oncogene homolog 1
10.52 11.01 0.012




ras-related C3 botulinum 
toxin substrate 1
10.79 10.43 0.005
nitric oxide synthase (DBSS) 5.23 5.78 0.001
n = 32 for vehicle; n = 3 for omeprazole-treated group.
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In conclusion, the use of PPIs might reduce the antitumor 
activity of bevacizumab in patients receiving bevacizumab.
4 |  MATERIALS AND METHODS
4.1 | Analysis of the FAERS database
The FAERS data sets for the third quarter of 2010 to the sec-
ond quarter of 2015 were obtained from the FDA website 
(https://www.fda.gov/Drugs/ Guida nceCo mplia nceRe gulat 
oryIn forma tion/Surve illan ce/Adver seDru gEffe cts/ucm08 
2193.htm). Following the FDA’s recommended method, we 
used the most recent case numbers to exclude duplicate reports 
(out of a total of 4331802 reports) and analyzed the remaining 
3724555 reports. The definition of hypertension was based 
on the 10 terms from the Standardized Medical Dictionary 
for Regulatory Activities (MedDRA) Queries [Hypertension] 
(SMQ code: 20000147), published in MedDRA/J ver 19.0, 
by the International Council for Harmonisation.
FAERS reports were classified into four groups: (a) re-
ceived bevacizumab and reported hypertension, (b) received 
bevacizumab but did not report hypertension, (c) did not re-
ceive bevacizumab but reported hypertension, and (d) did not 
receive bevacizumab and did not report hypertension. The 
ROR was used to signal detection and was calculated using 
the following equation.16,33
Letters a, b, c, and d indicate the number of individuals in 
each group. If the lower limit of the 95% CI was >1, it was 
assumed that there was a relationship between the drug use 
of interest and hypertension report. Conversely, if the upper 
limit of the 95% CI <1, we assumed that there was an asso-
ciation between the drug use of interest and reduced hyper-
tension report.
4.2 | Analysis of the medical chart review
In this retrospective study, we investigated patients’ medi-
cal records. This data was collected from the medical re-
cords of patients who visited our hospital. Patients aged 
≥18 years who were diagnosed with colorectal cancer at The 
Tokushima University Hospital between January 2010 and 
December 2015 and were treated with bevacizumab combina-
tion XELOX, or mFOLFOX6 for the first time, and patients 
with evaluated lesions using Response Evaluation Criteria in 
Solid Tumors (RECIST) were included. Patients who were 
treated with <1 course of bevacizumab, failed to follow-up, 
and had missing values were excluded. This study was ap-
proved by the Ethics Committee of Tokushima University 
Hospital (Approval Number: 2962-1).
The following data were extracted from patient charts: age 
at diagnosis, sex, cancer type, stage at diagnosis (using the 
6th edition AJCC system), Eastern Cooperative Oncology 
Group PS, bevacizumab dose, treatment duration, blood pres-
sure, and PPI-use. Patients were considered to have received 
concomitant PPIs if they had been prescribed PPIs continu-
ously during the bevacizumab treatment period. Blood pres-
sure was measured by the nurse prior to administration of 
bevacizumab for each cycle. The event of hypertension in 
patients receiving bevacizumab was defined according to 
the Common Terminology Criteria for Adverse Events v 4.0 
(CTCAE v 4.0): an increase in blood pressure of <20 mmHg, 
an increase in blood pressure to ≥150/100 mmHg, or hyper-
tension requiring initiation or increase in therapeutic medi-
cation. Those who were taking antihypertensive medication 
Calculation for ROR: ROR=(a∕b) ∕ (c∕d) ,
95%CI= exp (log (OR)±1.96 square 1∕a+1∕b+1∕c+1∕d)
F I G U R E  1  Effect of proton pump inhibitors to cell survival and promotion of angiogenesis. (A) Cell viability in HUVEC(n = 5) and 
(B) h-VEGFA mRNA expression in LS174T(n = 7) treated with PPIs or Famotidine or CoCl2 at 100 µM for 24 h. Ome; omeprazole, Eso; 
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before bevacizumab treatment were considered “taking an-
tihypertensive medication” and those who started antihy-
pertensive medication after bevacizumab treatment were 
considered “not taking antihypertensive medication.” The 
stage of cancer was extracted from the medical records, and 
relapse cases were considered as stage IV.
Treatment response was assessed according to RECIST 
version 1.0 as follows: CR, PR, SD, and PD. The primary 
endpoint was assessed using the ORR, which is the number 
of patients achieving CR or PR divided by the number of pa-
tients evaluated. Disease control was defined as the number 
of patients achieving CR, PR, and SD divided by the number 
of patients assessed.
4.3 | Analysis of the GEO and KEGG 
PATHWAY databases
Microarray gene expression data were obtained from the 
National Center for Biotechnology Information (NCBI) GEO 
database (http://www.ncbi.nlm.nih.gov/geo/) (accession 
number GSE59927).We analyzed expression data using sam-
ples analyzed in the livers of rats receiving oral omeprazole 
(30 mg/kg, once daily/5 days) or vehicle (carboxymethylcel-
lulose), focusing on genes involved in the VEGF signaling 
pathway extracted from the KEGG PATHWAY database 
(entry number: MAP04370 http://www.genome.jp/dbget 
-bin/www_bget?pathw ay:map04370). The expression levels 
of each gene were shown in relation to controls by inverting 
the log2-transformed microarray data to the original scale.
We chose a rat model and not a human model for this 
analysis because in reality, the patients were treated with a 
number of drugs in combination. Thus, it was ethically diffi-
cult to administer PPIs alone to humans, and to obtain tissue 
samples for comparison before and after PPI administration. 
Therefore, to exclude the effects of concomitant drugs, in 
vivo experiments were needed to investigate the effects of 
these drugs.
4.4 | Real-time PCR and cell 
proliferation assay
The LS174T (human colon cancer cells) and HUVEC were 
cultured in α-MEM supplemented with 5% fetal bovine 
serum and 10  mg/mL of 1% (v/v) penicillin streptomycin 
(Sigma Aldrich, MO, USA). All cells were incubated at 37°C 
in a humidified atmosphere containing 5% (v/v) CO2.
HUVEC were cultured in 96-well plates and then exposed 
to PPI: omeprazole, esomeprazole, pantoprazole, rabepra-
zole, lansoprazole (100  μM), famotidine (100  μM), CoCl2 
(100 μM), and DMSO (0.1% v/v) for 24 hours, followed by 
incubation at 37°C in a humidified atmosphere containing 
5% (v/v) CO2. 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H 
tetrazolium bromide (MTT) was then added, and the cell pro-
liferation rate was measured.
LS174T cells were used to investigate gene expression. 
Cells were seeded in 6-well plates and incubated for 24 hours, 
then exposed to PPI: esomeprazole, pantoprazole, omepra-
zole, (10 μM), famotidine (100 μM), CoCl2 (100 μM), and 
DMSO (0.1% v/v) for 24 hours. Total RNA was extracted 
from cells using ISOGEN (NIPPON GENE) according to 
the manufacturer's protocol. Total RNA was reverse tran-
scribed to cDNA using Prime ScriptTM RT reagent Kit with 
gDNA Eraser (TaKaRa). The cDNA product was used as a 
template for Polymerase Chain Reaction (PCR) amplification 
in a total volume of 10 µl, and the PCR condition were as 
follows: 95°C for 2 minutes, followed by 40 cycles at 95°C 
for 5 seconds, 60°C for 30 seconds, and 95°C for 5 seconds. 
Reactions were conducted on a CFX96 Real-time PCR 
Detection System (Bio-Rad). All data were analyzed with the 
CFX Manager Software (Bio-Rad). The data were analyzed 
using the delta cycle threshold method and calculated based 
on the Cq values; the expression of each gene was normalized 
to 36B4. Gene-specific primer pairs were used: h-VEGFA: 
(F) 5'-AGGAGGAGGGCAGAATCATC-3’, (R) 5'-ATGTC 
CACCAGGGTCTCGAT-3’; 36B4: (F) 5'-GCTCCAAGCAG 
ATGCAGCA-3’, (R) 5'-CCGGATGTGAGGCAGCAG-3'.
4.5 | Statistical analysis
For FAERS analysis, Microsoft Access 2013 was used for the 
FAERS database construction and R ver 3.2.1 (R Foundation 
for Statistical Computing, Vienna, Austria) was used for sta-
tistical analysis using the Fisher's exact test. For the retro-
spective chart review, the Mann-Whitney U-test was used as 
the distribution was not normal. Differences between cate-
gorical values were estimated using the chi-square or Fisher's 
exact test for comparisons with cells <5. Data obtained from 
the pathway analysis of RT-PCR experiments were per-
formed using the Dunnett's test. All recorded P values were 
two-sided, and P values <0.05 were considered significant.
The continuous variable case records are shown as mean 
± standard deviation. The demographic characteristics were 
evaluated with descriptive statistics. Student's t test with 
Welch's correction was used when the data distribution was 
normal, and the Mann-Whitney U-test was used when the 
distribution was not normal.
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